ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice.
Obstet Gynecol. 2018 Jun;131(6):e194-e199
Authors:
Abstract
Aromatase inhibitors have been used for the treatment of breast cancer, ovulation induction, endometriosis, and other estrogen-modulated conditions. For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency. Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding. For women with polycystic ovary syndrome and a body mass index greater than 30, letrozole should be considered first-line therapy for ovulation induction because of the increased live birth rate compared with clomiphene citrate. Lifestyle changes that result in weight loss should be strongly encouraged. Aromatase inhibitors are a promising therapeutic option that may be helpful for the management of endometriosis-associated pain in combination therapy with progestins.
PMID: 29794680 [PubMed - in process]
Source: Obstetrics and Gynecology - Category: OBGYN Tags: Obstet Gynecol Source Type: research
More News: Bleeding | Breast Cancer | Cancer | Cancer & Oncology | Clomid | Endometrial Cancer | Endometriosis | OBGYN | Orthopaedics | Osteoporosis | Ovaries | Pain | Pain Management | Polycystic Ovary Syndrome | Tamoxifen | Thrombosis | Weight Loss | Women